adra1b-protein

Migration, Crosslink

📖

adra1b-protein

active

wiki page Created: 2026-04-02T07:19:13 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-adra1b-protein

📖 Wiki Page

protein2242 wordssynced 2026-04-02

ADRA1B Protein — Alpha-1B Adrenergic Receptor

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">ADRA1B Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>ADRA1B, Alpha-1B Adrenergic Receptor</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>[ADRA1B](https://www.ncbi.nlm.nih.gov/gene/147)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P15888](https://www.uniprot.org/uniprot/P15888)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~50-60 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cell membrane, caveolin-rich domains</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Class A GPCR, α1-adrenergic family</td></tr>
<tr><td><strong>Ligand</strong></td><td>Norepinephrine, epinephrine</td></tr>
<tr><td><strong>Signal Transduction</strong></td><td>Gq/11 protein, PLCβ, Ca²⁺</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">14 edges</a></td>
</tr>
</table>
</div>

Overview

...

ADRA1B Protein — Alpha-1B Adrenergic Receptor

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">ADRA1B Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>ADRA1B, Alpha-1B Adrenergic Receptor</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>[ADRA1B](https://www.ncbi.nlm.nih.gov/gene/147)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P15888](https://www.uniprot.org/uniprot/P15888)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~50-60 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cell membrane, caveolin-rich domains</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Class A GPCR, α1-adrenergic family</td></tr>
<tr><td><strong>Ligand</strong></td><td>Norepinephrine, epinephrine</td></tr>
<tr><td><strong>Signal Transduction</strong></td><td>Gq/11 protein, PLCβ, Ca²⁺</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">14 edges</a></td>
</tr>
</table>
</div>

Overview

The Alpha-1B Adrenergic Receptor (ADRA1B) is a G protein-coupled receptor (GPCR) that mediates the effects of norepinephrine and epinephrine on target tissues. It belongs to the α1-adrenergic receptor subfamily, which includes ADRA1A (α1A), ADRA1B (α1B), and ADRA1D (α1D) subtypes. ADRA1B plays important roles in cardiovascular function, smooth muscle contraction, neurotransmission, and has emerged as a significant player in neurodegenerative disease pathogenesis [1].[@c2009]

In the central nervous system (CNS), ADRA1B is involved in arousal, attention, stress responses, and cognitive function. The receptor is widely distributed in brain regions critical for memory and executive function, including the [prefrontal cortex](/brain-regions/prefrontal-cortex), [hippocampus](/brain-regions/hippocampus), and [hypothalamus](/brain-regions/hypothalamus). Dysregulation of α1-adrenergic signaling has been implicated in Alzheimer's disease (AD), Parkinson's disease (PD), and vascular cognitive impairment [2].[@mj2000]

The noradrenergic system, which uses norepinephrine (NE) as its primary neurotransmitter, is severely affected in neurodegenerative diseases. The locus coeruleus (LC), the main source of norepinephrine in the brain, undergoes significant degeneration in both AD and PD.[@j2003] This degeneration leads to widespread dysregulation of adrenergic signaling, including ADRA1B-mediated pathways, contributing to cognitive decline, neuropsychiatric symptoms, and autonomic dysfunction [3].

Structure

ADRA1B has the canonical seven-transmembrane domain structure characteristic of Class A GPCRs:

Transmembrane Domains

Seven α-helices: TM1-TM7 cross the lipid bilayer at angles of ~20-30°
Conserved sequence motifs: Characteristic of rhodopsin-like GPCRs
DRY motif at the boundary of TM3 and intracellular loop 2
NPxxY motif in TM7
CWxP motif in TM6
Orthosteric binding pocket: Located deep within the transmembrane bundle, binds catecholamines (norepinephrine, epinephrine)
Binding site architecture: Conserved aspartic acid in TM3 (Asp125) serves as a primary anchor for the amine group of catecholamines

Extracellular Domain

N-terminal tail: Short extracellular sequence (approximately 30 amino acids)
Loop regions: Three extracellular loops (ECL1-ECL3)
ECL1: ~15-20 amino acids, contains conserved cysteine for disulfide bond
ECL2: Largest extracellular loop, ~40-50 amino acids
ECL3: Shortest, ~10-15 amino acids

Intracellular Domain

C-terminal tail: Contains serine/threonine phosphorylation sites (~50 amino acids)
G protein coupling region: Located in intracellular loops 2 and 3
Third intracellular loop: Critical for Gq/11 protein specificity

Structural Features Unique to ADRA1B

ADRA1B exhibits subtype-specific structural characteristics:

Ligand binding selectivity: The binding pocket differs from ADRA1A and ADRA1D
G protein coupling: Highly selective for Gq/11 over other G proteins
Palmitoylation: C-terminal cysteine for membrane anchoring
Glycosylation: N-terminal N-linked glycosylation sites

Crystal Structure and Modeling

Recent advances in GPCR structural biology have enabled detailed understanding of α1-adrenergic receptor structure:

Cryo-EM structures: High-resolution structures of related α1 receptors
Molecular dynamics: Simulations revealing ligand-induced conformational changes
Allosteric sites: Identification of potential allosteric modulatory sites

Normal Function

Signal Transduction Cascade

ADRA1B activates the Gq/11 signaling pathway through a well-characterized cascade [4]:

Ligand binding: Norepinephrine or epinephrine binds to the orthosteric site

Conformational change: Receptor adopts active conformation (R* state)

G protein activation: Gαq subunit exchanges GDP for GTP

Effector activation: Gαq-GTP activates phospholipase Cβ (PLCβ)

Second messenger generation: PLCβ hydrolyzes PIP₂ to IP₃ and DAG

Calcium release: IP₃ binds receptors on endoplasmic reticulum, releasing Ca²⁺

PKC activation: DAG and Ca²⁺ activate protein kinase C (PKC)

Cellular responses: Multiple downstream effects including smooth muscle contraction

Physiological Roles

Cardiovascular System

Vascular tone: Vasoconstriction in peripheral vasculature, particularly in skin, splanchnic, and renal beds
Blood pressure regulation: Contributes to maintenance of blood pressure through alpha-adrenergic vasoconstriction
Cardiac function: Positive inotropic effects, though less prominent than β-adrenergic effects

Smooth Muscle

Bladder: Contraction of detrusor muscle, regulation of urinary function
Gastrointestinal tract: Modulation of intestinal motility and tone
Uterus: Uterine smooth muscle contraction
Pupil: Radial muscle contraction causing mydriasis (pupillary dilation)

Central Nervous System

Arousal and wakefulness: Noradrenergic signaling promotes cortical activation
Attention: Modulation of attentional processes, particularly in prefrontal cortex
Stress response: Activation of sympathetic nervous system via hypothalamic-pituitary-adrenal (HPA) axis modulation
Cognitive function: Influences working memory and executive function
Thermoregulation: Brown adipose tissue thermogenesis

Expression Pattern

ADRA1B is expressed in multiple tissue types [5]:

Peripheral Tissues

Liver: Hepatocyte expression, affects gluconeogenesis
Kidney: Renal vasculature and tubules
Heart: Myocardial cells, coronary vasculature
Vasculature: Arterial and venous smooth muscle
Adipose tissue: White and brown adipose tissue

Central Nervous System

Cerebral cortex: Layer 5 pyramidal neurons
Hippocampus: CA1 and CA3 regions, dentate gyrus
Hypothalamus: Paraventricular nucleus, supraoptic nucleus
Amygdala: Central and basolateral nuclei
Locus coeruleus: Noradrenergic cell bodies
Cerebellum: Purkinje cells, deep cerebellar nuclei

Glial Cells

Astrocytes: Modulation of astrocyte function and blood-brain barrier
Microglia: Regulation of microglial activation and neuroinflammation

G Protein Coupling Specificity

ADRA1B exhibits high selectivity for Gq/11 proteins:

Gαq family: Primary coupling to Gq, G11, G14, G16
Gβγ subunits: Also released upon activation, modulate additional effectors
Alternative coupling: Can couple to Gz in certain cell types
Bias signaling: Ligand-directed signaling (biased agonism) possible

Role in Neurodegeneration

Alzheimer's Disease

ADRA1B plays a multifaceted role in Alzheimer's disease pathogenesis [6]:

Vascular Dysfunction

ADRA1B-mediated vascular signaling contributes to cerebral vascular dysfunction in AD:

Cerebral autoregulation: Impaired α1-adrenergic control of cerebral blood flow
Blood-brain barrier (BBB): ADRA1B activation affects BBB permeability
Angiogenesis: Dysregulated vascular endothelial growth factor signaling
Amyloid angiopathy: Interaction with cerebral amyloid angiopathy (CAA)

Neuroinflammation

Noradrenergic signaling through ADRA1B modulates neuroinflammation [7]:

Microglial activation: α1-adrenergic signaling promotes pro-inflammatory microglial phenotype
Cytokine production: Increased IL-1β, TNF-α, IL-6 release
Neuroinflammation amplification: Chronic noradrenergic dysfunction creates inflammatory feed-forward loop
Astrocyte regulation: Modulation of astrocyte reactivity and function

Cognitive Dysfunction

ADRA1B signaling affects cognitive processes:

Working memory: Prefrontal cortical α1-adrenergic modulation of working memory
Attention: Noradrenergic attention system dysregulation
Synaptic plasticity: Effects on long-term potentiation (LTP) and memory consolidation
Sleep-wake cycle: Disrupted norepinephrine signaling affects sleep architecture

Therapeutic Implications

α1-adrenergic modulation represents a therapeutic target in AD:

α1 antagonists: Prazosin shows promise in preclinical and clinical studies
Peripheral vs. central effects: Challenge of achieving central effects without peripheral side effects
Combination therapy: Potential for combined α1 and β-adrenergic modulation
Timing considerations: Optimal intervention in disease course

Parkinson's Disease

ADRA1B contributes to several aspects of Parkinson's disease [8]:

Autonomic Dysfunction

PD patients commonly exhibit autonomic impairments:

Orthostatic hypotension: α1-adrenergic dysregulation contributes to blood pressure dysregulation
Urinary dysfunction: Bladder overactivity related to noradrenergic signaling
Gastrointestinal dysmotility: Colonic dysfunction in PD
Sexual dysfunction: Autonomic involvement in PD

Neuroprotection

α1-adrenergic signaling has neuroprotective potential:

Dopaminergic neuron survival: Noradrenergic modulation of nigral neuron survival
Oxidative stress: Modulation of oxidative stress responses
Mitochondrial function: Effects on mitochondrial dynamics and function
Neuroinflammation: Anti-inflammatory vs. pro-inflammatory effects

L-DOPA-Induced Dyskinesia

ADRA1B may contribute to L-DOPA-induced dyskinesia (LID):

Dyskinesia development: Role of noradrenergic signaling in LID pathophysiology
α1-adrenergic antagonists: Potential for reducing dyskinesia severity
Combined dopaminergic and noradrenergic targeting: Novel therapeutic strategies

Vascular Cognitive Impairment

ADRA1B plays a significant role in vascular cognitive impairment (VCI):

Cerebral Autoregulation

Impaired blood flow regulation: Dysfunctional α1-adrenergic control
White matter damage: Hypoperfusion-related white matter lesions
Microinfarcts: Contribution to microvascular pathology

Ischemic Injury

Stroke recovery: Role in post-stroke rehabilitation
Neuroprotection: Potential for protecting against ischemic damage
Angiogenesis: Effects on post-ischemic recovery

Mixed Dementia

AD/Vascular overlap: Interaction between vascular pathology and AD
Therapeutic targeting: Modulating cerebral vasculature

Stroke and Recovery

ADRA1B affects stroke pathophysiology and recovery:

Acute Phase

Cerebral vasoconstriction: Role in acute blood flow responses
Blood-brain barrier: Effects on BBB disruption
Excitotoxicity: Interaction with glutamate excitotoxicity

Recovery Phase

Neurogenesis: Effects on adult neurogenesis
Angiogenesis: Role in post-stroke vascular remodeling
Functional recovery: Modulation of rehabilitation outcomes

Neuroprotection Mechanisms

ADRA1B signaling can be neuroprotective through [9]:

Anti-apoptotic effects: PKC-mediated pro-survival signaling
Antioxidant responses: Activation of Nrf2 pathway
Heat shock protein induction: HSP70 and other protective proteins
Autophagy modulation: Regulation of autophagic processes

Therapeutic Targeting

Drug Development

| Drug Class | Mechanism | Example | Clinical Use | Status |
|------------|-----------|---------|--------------|--------|
| Antagonists | Block receptor | Prazosin | Hypertension, PTSD | Approved |
| Partial agonists | Weak activation | Midodrine | Orthostatic hypotension | Approved |
| Selective antagonists | α1B-selective | Terazosin | BPH | Approved |
| Inverse agonists | Constitutive activity | -- | Research | Preclinical |
| Allosteric modulators | Bind allosteric site | -- | Research | Preclinical |

Clinical Applications

Approved Indications

Hypertension:

Prazosin, doxazosin, terazosin: First-generation α1 blockers
Effect on blood pressure: Reduction of peripheral vascular resistance
Side effects: Orthostatic hypotension, reflex tachycardia

Benign Prostatic Hyperplasia (BPH):

Terazosin, doxazosin: α1-adrenergic blockade in prostate
Effect: Reduced urinary outlet obstruction
Additional benefit: May improve lipid profile

Post-Traumatic Stress Disorder (PTSD):

Prazosin: Reduces trauma-related nightmares and sleep disturbance
Mechanism: Central α1-adrenergic blockade
Evidence: Multiple clinical trials support efficacy

Orthostatic Hypotension:

Midodrine: Direct α1-adrenergic agonist
Effect: Increase peripheral vascular tone
Use: Neurogenic orthostatic hypotension

Off-Label Uses

Alzheimer's Disease:

Prazosin: Investigated for cognitive enhancement
Evidence: Mixed results from clinical trials
Challenge: Central vs. peripheral effects

Parkinson's Disease:

Doxazosin, terazosin: Potential neuroprotective effects
Evidence: Preclinical and some clinical data
Consideration: Autonomic symptom management

CNS Applications in Development

Cognitive Enhancement

Target: Prefrontal cortical ADRA1B
Approach: Selective antagonists or biased agonists
Challenge: Achieving central activity without peripheral effects

Neuroprotection

Target: Multiple pathways including anti-apoptotic, antioxidant
Approach: Modulation of ADRA1B signaling
Potential: Disease-modifying effects

Stroke Recovery

Target: Cerebral vasculature and neurogenesis
Approach: α1-adrenergic modulation
Evidence: Preclinical models show promise

Pharmacokinetics

Absorption: Well-absorbed orally
Distribution: Variable CNS penetration (prazosin > terazosin)
Metabolism: Hepatic metabolism (CYP enzymes)
Elimination: Renal and hepatic clearance

Adverse Effects

Orthostatic hypotension: Most common, especially initial dosing
Reflex tachycardia: Due to vasodilation
Sexual dysfunction: Erectile dysfunction
Central effects: Drowsiness, fatigue, headache

Animal Models

Knockout Models

ADRA1B knockout mice:

Cardiovascular: Hypotension, reduced pressor response
Smooth muscle: Impaired contractile responses
Behavioral: Altered stress response, anxiety-like behavior
Metabolic: Altered energy homeostasis

Transgenic Models

Overexpression studies: Effects on blood pressure, anxiety
Conditional knockout: Tissue-specific deletion
Humanized models: Expressing human ADRA1B

Disease Models

Hypertension models: DOCA-salt, spontaneous hypertension
Stroke models: Middle cerebral artery occlusion (MCAO)
AD models: APP/PS1, 5xFAD with ADRA1B modulation
PD models: MPTP, 6-OHDA with ADRA1B studies

Genetic Variation

Polymorphisms

Coding variants: Affect receptor function and pharmacology
Promoter variants: Influence expression levels
Linkage disequilibrium: Haplotype structure
Ethnic variation: Different allele frequencies across populations

Clinical Implications

Drug response: Variability in response to α1 blockers
Disease risk: Potential association with cardiovascular disease
Pharmacogenomics: Personalized medicine applications

Biomarkers

Peripheral Biomarkers

Plasma NE levels: Reflect sympathetic activity
ADRA1B expression: On peripheral blood cells
Genetic markers: SNP associations

CNS Biomarkers

Imaging: PET ligands for α1-adrenergic receptors
CSF markers: Limited evidence
Functional measures: Blood pressure responses

Research Directions

Biomarkers

Peripheral ADRA1B: As sympathetic activity marker
Genetic variants: Predict drug response
Expression studies: In neurodegenerative disease

Gene Therapy

Viral vector delivery: Target CNS ADRA1B
CRISPR approaches: Edit ADRA1B gene
RNA interference: Reduce ADRA1B expression

Structural Studies

Cryo-EM: High-resolution structure determination
Allosteric sites: Novel drug binding sites
Dynamics: Conformational changes upon activation

Novel Therapeutics

Biased agonists: Signaling pathway-selective compounds
Peripheral restrictions: Limit CNS side effects
Combination approaches: Multi-target strategies

External Links

[UniProt P15888](https://www.uniprot.org/uniprot/P15888)
[NCBI Gene ADRA1B](https://www.ncbi.nlm.nih.gov/gene/147)
[IUPHAR Database](https://www.guidetopharmacology.org/record/GPCR/1489)
[Human Protein Atlas](https://www.proteinatlas.org/ENSG00000170156-ADRA1B)
[GeneCards ADRA1B](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADRA1B)

References

[Perez et al., Alpha1-adrenergic receptors in brain: from mapping to function (Neuroscientist, 2009)](https://pubmed.ncbi.nlm.nih.gov/19151768/)

[Cai et al., Adrenergic signaling in neurodegenerative diseases (Brain Res, 2022)](https://pubmed.ncbi.nlm.nih.gov/35653789/)

[Roch et al., Alpha1-adrenergic receptors in Alzheimer's disease (Neurobiol Aging, 2021)](https://pubmed.ncbi.nlm.nih.gov/33852876/)

[Khan et al., Alpha1-adrenergic receptor subtypes: structure, function and clinical significance (J Clin Pharm Ther, 2000)](https://pubmed.ncbi.nlm.nih.gov/11250556/)

[Hrometz et al., Alpha1-adrenergic receptor subtypes (J Pharmacol Exp Ther, 1999)](https://pubmed.ncbi.nlm.nih.gov/10336524/)

[Johansson et al., Norepinephrine and alpha1-adrenergic signaling in neuroinflammation (J Neuroinflammation, 2020)](https://pubmed.ncbi.nlm.nih.gov/32933521/)

[Chen et al., Alpha1-AR signaling in cerebral blood flow regulation (J Cereb Blood Flow Metab, 2018)](https://pubmed.ncbi.nlm.nih.gov/29510739/)

[Maciejewski et al., Terazosin and doxazosin in Parkinson disease (Mov Disord, 2018)](https://pubmed.ncbi.nlm.nih.gov/30251244/)

[Mittal et al., Prazosin and cognitive function in Alzheimer's disease (J Alzheimers Dis, 2017)](https://pubmed.ncbi.nlm.nih.gov/28609228/)

[Strosberg, Structure and function of alpha1-adrenergic receptors (Pharmacol Rev, 1999)](https://pubmed.ncbi.nlm.nih.gov/10562837/)

📖 View canonical wiki page →

Related Entities

ADRA1BPROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-adra1b-protein
kg_node_id	ADRA1BPROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-330e2b5dfad5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-adra1b-protein'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

45%

Debates

0

Incoming

9

Outgoing

10

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

adra1b-protein

ADRA1B Protein — Alpha-1B Adrenergic Receptor

Overview

ADRA1B Protein — Alpha-1B Adrenergic Receptor

Overview

Structure

Transmembrane Domains

Extracellular Domain

Intracellular Domain

Structural Features Unique to ADRA1B

Crystal Structure and Modeling

Normal Function

Signal Transduction Cascade

Physiological Roles

Cardiovascular System

Smooth Muscle

Central Nervous System

Expression Pattern

Peripheral Tissues

Central Nervous System

Glial Cells

G Protein Coupling Specificity

Role in Neurodegeneration

Alzheimer's Disease

Vascular Dysfunction

Neuroinflammation

Cognitive Dysfunction

Therapeutic Implications

Parkinson's Disease

Autonomic Dysfunction

Neuroprotection

L-DOPA-Induced Dyskinesia

Vascular Cognitive Impairment

Cerebral Autoregulation

Ischemic Injury

Mixed Dementia

Stroke and Recovery

Acute Phase

Recovery Phase

Neuroprotection Mechanisms

Therapeutic Targeting

Drug Development

Clinical Applications

Approved Indications

Off-Label Uses

CNS Applications in Development

Cognitive Enhancement

Neuroprotection

Stroke Recovery

Pharmacokinetics

Adverse Effects

Animal Models

Knockout Models

Transgenic Models

Disease Models

Genetic Variation

Polymorphisms

Clinical Implications

Biomarkers

Peripheral Biomarkers

CNS Biomarkers

Research Directions

Biomarkers

Gene Therapy

Structural Studies

Novel Therapeutics

See Also

External Links

References

💬 Discussion